Elucidating and testing causal drivers of inflammation triggered prostatic early lesions

阐明和测试炎症引发前列腺早期病变的因果驱动因素

基本信息

  • 批准号:
    10518915
  • 负责人:
  • 金额:
    $ 37.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-15 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract: We have proposed that inflammatory infiltrates in human PIA reflect an anti-prostatic pro-inflammatory immune response that serves as a hotbed for cancer initiation. Interestingly, the acute and chronic inflammatory cell infiltrates common in PIA are generally not seen in most prostate cancers. These observations have prompted our proving ground hypothesis which suggests that in order for prostate cancer to develop past these initiated steps in PIA to bona fide pre-neoplastic precursor (PIN) and to invasive carcinoma, this immune response must be abrogated. We observed upregulation of stress-response and inflammatory genes in human PIA luminal epithelial cells. These same genes (examples: GSTP1, PTGS2, and LTF ) are epigenetically silenced in PIN and early and metastatic invasive adenocarcinoma of the prostate. This led to a potential molecular mechanism in which a set of genes whose expression is highly induced in PIA undergo silencing to allow cells to emerge as PIN and invasive carcinoma. We show here that the major inflammatory mediator Stimulator of Interferon Genes (STING) is absent in normal prostate luminal cells, is highly induced in intermediate luminal cells in PIA, and is not expressed in the vast majority of human PIN and adenocarcinomas. We hypothesize STING expression in PIA luminal cells is required for inflammation, cell injury, and the prostate cancer initiation. Second, we hypothesize that in a subset of PIA cells, epigenetic silencing of STING (or of its downstream signaling activity) results in dampening of the immune response, imparting a growth advantage by allowing them to emerge as neoplastic cells. We will test these hypotheses in as follows. In Specific Aim 1 we will genetically and pharmacologically test the STING activation hypothesis for developing acute and chronic inflammation, PIA and PIN in the mouse prostate using our unique mouse model of IL1-beta induced prostatic inflammation and PIA progressing to PIN (IMPI mice). In Specific Aim 2 we will test the “epigenetic silencing of induced genes” hypothesis in human samples by performing a comprehensive characterization of DNA-methylation based epigenomic changes in mouse and human epithelial cells in the transitions from prostatic inflammatory lesions to neoplasia. Mechanistically, we hypothesize that STING (along with many other stress and inflammation induced genes) is epigenetically silenced at the transition stage of PIA to high grade PIN. In Specific Aim 3, we hypothesize that in "graduating" from the proving ground, neoplastic cells leave behind the pro-inflammatory microenvironment in PIA, and sculpt a microenvironment with reduced adaptive immune cells through recruitment of immune suppressive myeloid and lymphoid cells (e.g. MDSCs, M2 macrophages and Tregs) that help quell the cancer immune response. We will define the cellular composition and spatial architecture of microenvironment in mouse and human early precursor prostatic inflammatory lesions.
项目概要/摘要: 我们提出,人类PIA中的炎性浸润反映了抗前列腺促炎免疫 作为癌症开始的温床的反应。有趣的是,急性和慢性炎症细胞 PIA中常见的浸润通常在大多数前列腺癌中看不到。这些观察结果促使 我们的试验场假设表明,为了使前列腺癌发展超过这些, 启动步骤PIA真正的前肿瘤前体(PIN)和浸润性癌,这种免疫 回应必须取消。我们观察到人类应激反应和炎症基因的上调, PIA腔上皮细胞。这些相同的基因(例如:GST P1,PTGS 2和LTF)在表观遗传学上是沉默的 在PIN和前列腺的早期和转移性浸润性腺癌中。这导致了一种潜在的分子 一种机制,其中一组在PIA中高度诱导表达的基因经历沉默,以允许细胞 出现PIN和浸润性癌。我们在这里表明,主要的炎症介质刺激因子, 干扰素基因(STING)在正常前列腺腔细胞中不存在,在中间腔细胞中高度诱导, PIA中的细胞中表达,并且在绝大多数人PIN和腺癌中不表达。我们假设 PIA管腔细胞中的STING表达是炎症、细胞损伤和前列腺癌起始所需的。 第二,我们假设在PIA细胞的亚群中,STING(或其下游基因)的表观遗传沉默可能与PIA细胞的表观遗传沉默有关。 信号传导活性)导致免疫应答的抑制,通过允许它们 变成肿瘤细胞我们将测试这些假设如下。在具体目标1中,我们将遗传 并对STING激活假说进行了验证, 和PIN在小鼠前列腺中的作用, PIA进展为PIN(IMPI小鼠)。在特定目标2中,我们将测试“诱导基因的表观遗传沉默” 通过对基于DNA甲基化的DNA甲基化进行全面表征, 小鼠和人类上皮细胞从前列腺炎性病变向前列腺增生转变过程中的表观基因组变化 肿瘤形成从机制上讲,我们假设STING(沿着许多其他应激和炎症诱导) 基因)在PIA向高级PIN的过渡阶段表观遗传学沉默。在具体目标3中,我们 假设在从试验场“毕业”的过程中,肿瘤细胞留下了促炎性细胞, PIA中的微环境,并通过减少适应性免疫细胞来塑造微环境, 募集免疫抑制性髓样和淋巴样细胞(例如MDSC、M2巨噬细胞和TCFs), 帮助抑制癌症免疫反应。我们将定义的细胞组成和空间结构, 在小鼠和人类前列腺早期炎症病变的微环境中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANGELO Michael DE MARZO其他文献

ANGELO Michael DE MARZO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANGELO Michael DE MARZO', 18)}}的其他基金

Admin-Core-001
管理核心-001
  • 批准号:
    10933141
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer
前列腺炎性病变是侵袭性前列腺癌发展的试验场
  • 批准号:
    10698119
  • 财政年份:
    2022
  • 资助金额:
    $ 37.98万
  • 项目类别:
Elucidating and testing causal drivers of inflammation triggered prostatic early lesions
阐明和测试炎症引发前列腺早期病变的因果驱动因素
  • 批准号:
    10698123
  • 财政年份:
    2022
  • 资助金额:
    $ 37.98万
  • 项目类别:
Spatial and mechanistic assessment of the role of stromal fibroblasts in driving emergence of aggressive prostate and bladder cancer
基质成纤维细胞在推动侵袭性前列腺癌和膀胱癌出现中的作用的空间和机制评估
  • 批准号:
    10831131
  • 财政年份:
    2022
  • 资助金额:
    $ 37.98万
  • 项目类别:
TBEL Administrative Core
TBEL 行政核心
  • 批准号:
    10518914
  • 财政年份:
    2022
  • 资助金额:
    $ 37.98万
  • 项目类别:
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer
前列腺炎性病变是侵袭性前列腺癌发展的试验场
  • 批准号:
    10518913
  • 财政年份:
    2022
  • 资助金额:
    $ 37.98万
  • 项目类别:
TBEL Administrative Core
TBEL 行政核心
  • 批准号:
    10698120
  • 财政年份:
    2022
  • 资助金额:
    $ 37.98万
  • 项目类别:
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry
多学科综合基因组方法区分欧洲和非洲血统男性的致命性前列腺癌和惰性前列腺癌
  • 批准号:
    10253255
  • 财政年份:
    2015
  • 资助金额:
    $ 37.98万
  • 项目类别:
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry
多学科综合基因组方法区分欧洲和非洲血统男性的致命性前列腺癌和惰性前列腺癌
  • 批准号:
    9565036
  • 财政年份:
    2015
  • 资助金额:
    $ 37.98万
  • 项目类别:
TISSUE MICROARRAY
组织微阵列
  • 批准号:
    7304721
  • 财政年份:
    2006
  • 资助金额:
    $ 37.98万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了